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1    Introduction – DNA Transposons as Genetic Tools 
Transposons are special genetic elements that are capable of moving from one DNA locus to another. 
They were discovered in maize by Barbara McClintock in the 1940s, and these ground-breaking experi-
ments later earned her the Nobel Prize in 1983. Transposons can be classified based on their replication 
intermediate (Class I retrotransposons and Class II DNA transposons), on their replication manner (repli-
cative versus non-replicative transposons), or on their ability to disperse independently (autonomous 
versus non-autonomous elements) (Burns and Boeke, 2012). Once considered to be selfish units of repli-
cation, they are now believed to also represent inevitable driving forces for evolution, proven by their 
presence in all genomes examined so far (Kazazian, 2004; Hedges & Batzer, 2005; Feschotte & Pritham, 
2007). The human genome is not an exception, as approximately 45% of our genetic material is made up 
of transposons (Biemont & Vieira, 2006; Mills et al., 2006; Wicker et al., 2007; Goodier & Kazazian, 
2008; Solyom & Kazazian, 2012). The majority of the human transposons belong to the Class I re-
trotransposons (or RNA transposons) which move around by the replicative “copy and paste” mecha-
nism. These contain currently active mobile elements which by all means played a significant role in 
human evolution (Mills et al., 2007; Shen et al., 2011). Moreover, LINE-1 retrotransposons were recent-
ly proven to be responsible for certain types of somatic mozaicisms present in vertebrate neurons (Singer 
et al., 2010). Class II DNA transposons, however, make up a significantly smaller proportion (~3%) of 
the human genome. This moderate fraction might be attributable to the fact that the majority of them 
spread by the non-replicative “cut and paste” mechanism. In addition, none of the DNA transposons have 
been shown to be active in the human genome (Feschotte & Pritham, 2007; Collier & Largaespada, 2007; 
Izsvak et al., 2010; Solyom & Kazazian, 2012).  
Transposons as genetic tools have been widely used in invertebrate model organisms (Drosophila 
species or Caenorhabditis elegans), mainly exploiting active DNA transposons of the particular species. 
The most prominent examples are the P-elements which were used as proof of principle for the two com-
ponent transposon gene delivery system in Drosophila melanogaster (Rubin & Spradling, 1982; Spra-
dling & Rubin, 1982). For vertebrates, however, applications were limited to retrotransposons for a long 
time, with the obvious disadvantages of higher mutational rate (due to the reverse transcription process) 
and the long term genetic instability of the modified cells because of the potential remobilization of the 
integrated transgene (Uren et al., 2005; Ostertag et al., 2007). A significant breakthrough in vertebrate 
genetics was the creation of an artificial Tc1/Mariner-type transposon, the Sleeping Beauty (SB) system, 
which was the first DNA transposon proven to be active in vertebrates, including human cells (Ivics et 
al., 1997). Its simple structure (Figure 1) made it easy to modify and to establish a controllable system by 
separating the transposase from its targets (the originally flanking terminal repeat sequences), thereby 
allowing the controlled delivery of any gene of interest into the genome (Izsvak et al., 2000). However, 
the efficiency of the originally resurrected SB variant was still significantly lower than the widely used 
viral vectors so its potential seemed to be behind those other genetic vehicles, especially in human appli-
cations. 
The success of “awakening” a new active DNA transposon initiated a wave of research aiming at 
establishing efficient novel transposon systems applicable in human cells. Apart from other reconstructed 
species (such as the Frog Prince from Rana pipiens, Miskey et al., 2003), an active DNA transposon 
(Tol2) was discovered in medaka fish and successfully applied in various vertebrate species (Balciunas et 
al., 2006). Moreover, a transposon from another insect species (Trichoplusia ni) called piggyBac (PB) 
was shown to be highly active in human cells (Ding et al., 2005). In the meantime, hyperactive versions 
of the previously used DNA transposons were also established (Zayed et al., 2004; Baus et al., 2005; 
Pledger & Coates, 2005), opening the possibility of efficient non-viral gene delivery applications. The 
most promising of all was the 100 times more active form of SB (SB100x), providing a highly effective 
alternative to the existing viral gene delivery methods (Mates et al., 2009). 
In a recent study, the most hyperactive versions of three transposon systems (SB, PB and Tol2) 
were systematically tested and compared in terms of delivery efficiency, copy number and integration 
profile of the transgene (Grabundzija et al., 2010). It was revealed that SB and PB are the most efficient 
gene delivery vehicles and, although transposition efficiency is known to decrease with the cargo size 
(Izsvak et al., 2010), they are able to carry and integrate inserts of ≥10 kb, outweighing the packaging 
capacity of the most efficient viral vectors. It was also shown that in conditions where the amount of 
DNA transposon is limiting (modeling most gene therapy applications), SB is superior even to PB. 
Moreover, the integration profile of SB seems to be the most favorable one: in fact, it is the closest to 
random on the genomic level among all tested viral- and transposon-based systems so far (Vigdal et al., 
2002; Liu et al., 2005; Yant et al., 2005; Grabundzija et al., 2010), providing the lowest risk for inser-
tional mutagenesis and making the SB system particularly suitable for gene therapy applications. In addi-
tion, as opposed to PB, no potential endogenous elements resembling SB are present in the human ge-
nome (Ivics et al., 1997; Ivics et al., 2004) which is an important safety issue that further supported the 
initiation of a clinical trial experiment using this transposon system (Williams, 2008). 
 
 
Figure 1: The structure of the Sleeping Beauty transposon system. In the natural transposon, the 
transposase gene is flanked by untranslated regions (UTRs) that include the terminal Inverted 
Repeat Direct Repeat regions (IRDR-L and IRDR-R), containing binding sites for the 
transposase. When used as a gene delivery vector system, the transposase coding region is 
replaced by a gene of interest within the transposable element that is maintained in a plasmid. 
This non-autonomous transposon can be mobilized if the transposase is supplied in trans by 
expression from a separate plasmid vector containing a suitable promoter. Co-transfection of 
the two components into candidate cells provides the platform for transposition from the donor 
plasmid to the cellular genome. 
Considering all aspects, however, other efficient transposon systems with integration preferences in-
to transcriptionally active regions (such as the PB system, Wilson et al., 2007) might be more suitable 
when performing “traditional” forward genetic screens (Collier & Largaespada, 2005; Chew et al., 2011; 
Guo et al., 2011). Also, as the PB transposase is able to “tracelessly” remove the integrated transgene 
from the genome, it might be a method of choice when such a feature is desirable, exemplified by the 
removal of the reprogramming cassette after generating induced pluripotent stem cells from fibroblasts 
(Kaji et al., 2009; Woltjen et al., 2009). Nevertheless, there are still various aspects of the transposon-
based technology that should be rigorously tested. Such issues include the potential silencing of the 
transgene which is often the drawback of viral vectors (Ellis, 2005), especially in the case of embryonic 
stem cells which are particularly prone to silence viral promoters (Meilinger et al., 2009; Rowe et al., 
2010). So far, the already applied DNA transposon sequences did not seem to face this problem as in the 
case of SB the effect of silencing was shown to depend on the cargo sequence, and not on the transposon 
vector (Garrison et al., 2007; Zhu et al., 2010). 
According to gene therapy guidelines or mutagenesis protocols, one of the most important issues is 
the exact and fast determination of transgene copy numbers (Bian & Belmont, 2010; Sivalingam et al., 
2010; Huang et al., 2010). Various methods are available to perform this, including “traditional” blotting 
techniques (Southern blotting/dot blotting), or several polymerase chain reaction (PCR)-based techniques 
(Wicks et al., 2000; Devon et al., 1995). These usually involve the application of radioactively or fluo-
rescently labeled probes, or – depending on the nature of the transgene – utilize the inherent signal origi-
nating from the transgene itself (such as quantifying GFP fluorescence, Moeller et al., 2003). Apart from 
often requiring hazardous chemicals or being laborious, the general problem of these methods is that they 
are usually set up for a specific transgene, and changing the gene of interest will require optimizing the 
applied parameters of the method once again. Using the SB system in our laboratory, we aimed to devel-
op an accurate and fast method to quantify transposon copy numbers that is applicable to any SB-based 
gene delivery experiments without a priori optimization of the protocol. We worked out a real-time PCR 
technique which is independent of the transgene sequence, hence we named it a “transgene independent” 
quantitative PCR technology (Kolacsek et al., 2011). Apart from being sensitive, accurate and fast, this 
approach also offers a powerful non-radioactive technique as an alternative against other canonical meth-
odologies.  
In this chapter, using the SB transposon system as a prominent example, we address quantitative 
issues regarding the transposon-based gene delivery methods. We focus in detail on a transgene-
independent qPCR method recently developed in our laboratory, providing more information in depth on 
the theoretical background and the technical aspects of this methodology published earlier (Kolacsek et 
al., 2011). Additionally, we also cover a technique of measuring transposase activity at the excision 
phase of the reaction which allows comparative analysis of different transposase variants, different trans-
poson systems or different conditions of application. We believe that these quantitative aspects of trans-
posase activity are of great importance especially in light of the applicability of the DNA transposons for 
gene therapy purposes. 
2    Selecting and Separating Transgenic Clones after Transposition 
2.1    Selection Methodology 
The basis of generating stable transgenic clones is to apply the most efficient but the least harmful gene 
delivery into the chosen cell types. The SB transposon is the method of choice in this respect as it offers a 
stable transgene integration technology with the least mutagenic potential among all available gene de-
livery techniques (see Section 1 above). Nevertheless, the bottleneck of this technology is that it involves 
the transfection of DNA into the host cells which might have low efficiency rates for certain cell types, 
such as embryonic stem cells. It is therefore necessary to apply an efficient and preferably non-invasive 
selection protocol to establish homogenous transgene expressing cells following transfection and trans-
position. Selection methods may sometimes be carried out utilizing the expression of the transgene but 
very often it is inescapable to use an additional marker gene even at the expense of having a larger genet-
ic cargo, thereby lower delivery efficiency.   
In applications where the cell source is not limiting, various chemical selection methods such as 
antibiotic selection can be applied to enrich for transgene expressing cells (Figure 2). However, depend-
ing on the cell type, this method might significantly disturb cell physiology, therefore other approaches 
are necessary to be applied. For example, the advantage of using fluorescent markers is that the transfect-
ed cells can be separated by Fluorescent Activated Cell Sorting (FACS) analysis (Figure 3), although 
some cell types may not tolerate such physical stress and this method could also decrease cell viability. 
The aim is to optimize the transfection/selection procedure for the particular cell type reaching the high-
est possible gene delivery efficiency with the lowest possible cell mortality rate. 
2.2    Separating uniform clones 
Some transgenic applications (e.g. transgenic animals) require genetically uniform cell populations, 
which can be precisely characterized from various aspects, including copy number and integration sites. 
These features can contribute to the transgenic phenotype to a large extent. To develop a “reliable” des-
ignated method for copy number determination, our goal was to detect the lowest (1) stable copy per cell, 
and to clearly differentiate cells differing in copy numbers by one (e.g. cells carrying 2 copies from those 
with 1 or 3 copies). In other words, with this method we wanted to detect the copy number as corpuscular 
units in the cells. This was an important reason why we aimed at working with genetically uniform 
clones that carry the same transgenic cassette in different copy numbers. 
The simplest way for cloning is the threshold limit dilution of heterogeneous transgenic cell popu-
lation, previously selected by the transgene or the marker gene expression. In this method, a serial dilu-
tion of the cells is spread in a 96-well cell culture plate and those wells are considered to represent one 
clone where only one colony can be seen by microscopy; those cell clones are then further maintained 
and utilized. However, this method cannot be applied to all cell types, such as human embryonic stem 
cells which naturally grow only in clumps. In such cases, other manual methods may be applied, includ-
ing FACS selection or using cloning rings. 
2.3    Isolation of a Single Copy Insertion Serving as a Calibration Unit 
The major difficulty to start a particular copy number measurement project is the lack of reference sam-
ples with known copy numbers, also known as calibrators. If such samples determined by other tech-
niques are not available, the first step is to isolate clones carrying 1 copy of the transgene. 
Applying the hyperactive SB transposases often results in high copy numbers and working with 
such high efficiency transposon delivery may provide only small number of cells carrying 1 copy of the 
transgene. An obvious 1 copy clone source is the random integration of plasmids that most of the cases 
results in 1 transgenic copy. These integrations will contain the majority or the whole plasmid sequence, 
due to a random breakage of the transfected transposon vector. This can be achieved by transfecting the 
transposon donor plasmid either with the inactive mutant transposase variant or without the transposase 
expressing helper plasmid. Random integration is very ineffective, occurs usually in less than 1% of the 
transfected cells, but they can be selected out and can be cloned as well. This transfection serves as trans-
position control (Figure 2) resulting in traces of random integrations contrary to the active transposition, 
which has much higher integration efficiency, and it could provide us an excellent source of one copy 
clones. 
 
 
Figure 2: A typical experiments using SB tranposons: establishing transgenic HEK-293 cells 
expressing a puromycin resistance gene (puro). 2 days posttransfection, cells were passed into 
puromycin containing medium and selected for 10 days; living cells were visualized by 
Giemsa-staining following selection. The efficiency of transposition is obvious when 
comparing the selected cells after co-transfection with the transposase expressing helper 
plasmid (left) to the control experiment with the mutant transposase (right), the latter one 
indicating random integration events. As a negative control, non-selected cells are also shown 
in both experimental setups. 
 
Figure 3: Transgene selection after transposition using GFP expression. The expression 
cassette is delivered into HEK-293 cells by the SB transposon system resulting in a 
heterogeneous cell population (left panels). Transgenic cells were selected by FACS 
experiment (right panels). Fluorescence microscopy images of x200 magnification and FACS 
histograms of GFP intensities can be seen. Cell numbers (Counts) are shown as a function of 
fluorescence intensity plotted in a logarithmic scale. M1: marker indicating GFP expressing 
cells. 
3    Real-time PCR for Sequence Quantification 
The polymerase chain reaction (PCR) is a technique for the in vitro amplification of specific DNA se-
quences by the simultaneous primer extension of complementary strands of DNA (Kleppe et al., 1971; 
Mullis & Falona, 1987). It was a major development in molecular biology because it has simplified exist-
ing technologies and enabled a rapid development of new techniques which otherwise would not have 
been possible. PCR theoretically amplifies DNA exponentially, doubling the number of double stranded 
sequences present in each amplification cycle. After the logarithmic (log) phase of the reaction, the 
amount of the PCR product reaches the plateau phase (Figure 4). The amount of the product is propor-
tional to the starting sequence copy number during the log phase, providing the basis for reliable quanti-
tative comparisons.  
In traditional (endpoint) PCR, detection and quantification of the amplified sequence are per-
formed at the end of the reaction after the last PCR cycle, and involve post-PCR analysis such as gel 
electrophoresis, signal detection or image analysis. However, this allows only semi-quantitative analysis  
 
 
 Figure 4: Example of a real-time PCR experiment determining the efficiency of the GFP 
TaqMan® assay using a standard curve of dilution points. Twofold dilutions were prepared from 
gDNA of pooled transgenic clones with the same copy number. Measurements were performed 
on a StepOnePlus™ Real-Time PCR platform (Applied Biosystems, Foster City, CA). Data 
were analyzed with the StepOne™ Software v2.1. Amplification plot (left panel) shows the 
increase of fluorescence signal as a function of cycle numbers (baseline fluorescence is 
subtracted, hence ΔRn; different colors represent different dilution reactions). Typical 
parameters of the reaction are indicated. The right panel shows the standard curve derived from 
the experiment, showing Ct values as a function of gDNA input (expressed in logarithm of 
DNA quantity in nanograms). The line of best fit is calculated by linear regression using the 
standard points; the equation is also shown from which efficiency of the reaction is calculated. 
carried out in samples collected at multiple points throughout the amplification process, thus ensuring the 
analysis before the plateau is reached. This approach is usually combined with analysis of dilution series 
of the samples, it also requires known standards and provides a detection range of usually only tenfold 
difference (Chelly et al., 1988; Wang et al., 1989). In real-time quantitative PCR (qPCR), the amount of 
PCR product is measured at each cycle by the use of fluorescent dyes (Higuchi et al., 1992; Livak et al., 
1995). This ability to monitor the reaction during its exponential phase enables the user to determine the 
initial amount of target with great precision. Apart from being simple and fast, the powerful benefit of 
qPCR is the increased dynamic range of comparisons. 
The most popular fluorescent detection technologies are double-stranded DNA (dsDNA) binding 
agents, e.g. SYBR® Green, and fluorescent probes (Livak et al., 1995; Wittwer et al., 1997; Morrison et 
al., 1998). SYBR® Green signal is measured at the end of each extension step and the intensity depends 
on the amount of dsDNA that is present. This technology is simple because the dye can be added to any 
kind of sequence amplification, but lacks specificity because it will also bind to PCR artifacts, e.g. pri-
mer-dimers. Good primer design and quality of starting materials are critical to avoid nonspecific prod-
ucts. Specificity of the reaction could be assessed using a melting curve measured at the end of the reac-
tion (Figure 5). Melting curve determines the melting point (Tm) characteristic to the specific PCR prod-
uct which assures differentiation of valid qPCR reactions from PCR artifacts (Ririe et al., 1997). Those 
melting curves showing multiple peaks or one peak with rather different Tm than of the main product 
result from nonspecific PCR products indicating invalid reactions with false Ct values. 
 
Figure 5: Representative melting curve analysis of a SYBR® Green qPCR experiment. 
Derivative of the fluorescence signal of the reporter (Rn’) is shown as a function of the 
temperature. Two sequences (a target and an endogenous control) were amplified in various 
wells of this plate, therefore two melting peaks are visible; the melting temperature of the target 
is indicated. Different colors represent different reaction wells of the plate. 
Fluorescent oligonucleotide probes (e.g. TaqMan® probes) are designed to hybridize to the se-
quence amplified by the primers. At the annealing step of each cycle, the probe will bind to the target 
sequence, and will be subsequently cleaved by the 5’ nuclease activity of the polymerase during the ex-
tension phase. A dual labeled probe with a reporter dye at the 5’ end and a quencher dye at the 3’ end of 
the oligonucleotide will generate a fluorescent signal when the probe is degraded which is detected at the 
end of the extension phase (Livak et al., 1995; Heid et al., 1996). Probe-based systems provide highly 
specific detection of DNA, however, dual-labeling and complex design make them more expensive. 
In qPCR, the cycle number in which the signal appears at the beginning of the log phase is consid-
ered to be inversely correlated to the amount of starting template, as a higher amount will result in sooner 
amplification. Threshold is the level of signal that reflects a statistically significant increase over the 
baseline fluorescent signal (Figure 4). In most cases, the real-time PCR software automatically sets the 
threshold at least 10 times the standard deviation of the fluorescence value of the baseline. However, the 
positioning of the threshold can be set manually at any point in the exponential phase of PCR. Threshold 
cycle (Ct) is the cycle number determined by the software at which the amplification plot crosses the 
threshold. Passive reference dyes (usually added to the qPCR master mixes) are frequently used in qPCR 
to normalize the fluorescent signal of reporter dyes (Rn). This allows the correction of fluctuations in 
fluorescence that is non-PCR-based, e.g. changes from well to well in reagent concentration or volume, 
or in instrument scanning (Figure 4). 
Validation of the qPCR assay is generally carried out by the analysis of the slopes from standard 
curves. A standard curve is generated by plotting the results of a dilution series of the template against 
the Ct for each dilution (Figure 4). In theory, if the reaction is 100% efficient, the PCR duplicates the 
template in each cycle, and in the log scale of template amount, the slope will be –3.32 (1/[lg(x)-lg(2x)] = 
–3.32). The reaction efficiency is related to assay sensitivity, which can be calculated from the slope 
(Real Time PCR Handbook, http://tools.invitrogen.com/content.cfm?pageid=12257): 
Efficiency = 10(–1/slope) – 1. 
The template used to generate the standard curve should match – as closely as possible – that is being 
used for the experiment (e.g. the same total RNA or DNA sample). The dilution range or dynamic range 
should span the concentration range expected for the unknown samples. The simplest way to ensure this 
is pooling the unknown samples (such as gDNAs from transgenic clones), and using it as a standard. The 
acceptable range of the efficiency, which most scientists agree on is between 90% – 110%. If efficiency 
is higher than 100%, it can reflect an inhibitory effect. In this case, scaling down the starting material 
usually helps by lowering the concentration of the suspected inhibitor. The desirable window of 90 to 
110% defines the range of input template quantities that may be measured in a particular qPCR. 
In the following three sections, we describe three different approaches which could be applied to 
determine transgene copy numbers of transgenic clones using a real-time PCR-based strategy. 
4    Determining Transgene Copy Numbers of Transgenic Clones 
4.1 First Approach: Verifying Presumably One Copy Clones with Absolute Quantification using 
the Marker Sequence 
We generated SB transgenic clones carrying a GFP expressing cassette separating them by FACS analy-
sis. Few clones were prepared also from random integration experiments, being obvious sources of 1 
copy integrations as mentioned formerly. Since random integrations can be derived from breakage of the 
plasmid at any point, the presence of fluorescence in these clones assures the presence of the GFP tran-
scription unit, so the GFP sequence can be reliably used for the copy number analysis. Therefore, specific 
TaqMan® assays were designed for the two terminal Inverted Repeat Direct Repeat (IRDR) motifs of the 
SB transposon (left and right, IRDR-L and IRDR-R), as well as for the GFP sequence. Sequences of 
primers and probes can be found in our previous publication (Kolacsek et al., 2011). 
In the absence of a reference clone with known copy number, we have to compare the absolute Ct 
values to known plasmid dilutions containing the transposon sequence. The recommended amount of 
gDNA input is in the range of 10 to 40 ng (we used 30 ng) but other input size of the starting material can 
also be accepted if in previous pilot experiments, the efficiency at that point was shown to be in the de-
sired range. For calculations of the required plasmid dilutions, first we need to know how many genome 
copies are present in the 30ng gDNA input. The average molecular weight of a DNA base pair is 
618g/mol, so using the Avogadro’s number of 6.02 × 1023 entities/mol, the molecular weight of a single 
haploid genome is (3 × 109 bp/genome × 618 g/mol) / 6.02 × 1023 = 3.08 pg. Therefore, 30ng gDNA 
contains 30000 pg / 2 × 3.08 = 4870 copy of diploid cell genome and so a one copy clone must contain 
4870 copy of the transgene. (Genome weight of other species can be found in the genome size database 
at www.genomesize.com.) Since we used a plasmid of 5800 bp in length, for the signal equivalent to the 
single copy clone, we needed approximately 4870 × (5800 bp × 618 g/mol) / 6.02 × 1023 = 0.029 pg of 
plasmid input. Considering a plasmid with concentration of 100 ng/µl, at least a 3.45 × 106-fold dilution 
is required to be in the similar range. The equivalent plasmid amount was put in the middle of our stand-
ard curve and two neighboring points of twofold dilutions were taken for the standard curve (Figure 6). 
With this setup applying the GFP TaqMan® assay, 5317 ± 195 copy was calculated for a randomly inte-
grated GFP expressing clone, slightly differing from the desired 4870, estimating the copy number as 
(5317 ± 195) / 4870 = 1.09 ± 0.04. 
In absolute quantification, each template must have sufficient purity and the input amount needs to 
be precisely quantified. The accuracy of the assay is directly related to the quality of the standard curve. 
Several dilution steps preceding each assay have to be performed with special attention, however, no 
matter how much care is taken, real-time PCR sensitivity amplifies minute human errors. In addition, the 
plasmid template used to generate the standard curve might not be an ideal specimen as it might not real-
ly represent the complex properties of the unknown samples. Due to such difficulties, absolute quantifi-
cation seemed inconvenient for our routine transposon applications. Nevertheless, once we have success-
fully selected one copy clones, we could use them as reference samples for comparative analysis. 
 
 
Figure 6: Absolute quantification of a presumably one copy clone using the GFP TaqMan® 
assay: comparison of the Ct values to known plasmid dilutions. Ct values are shown as a 
function of the quantity. Standard curve points of plasmid dilutions around the expected 
quantity are shown in red, whereas Ct values measured for the clone were put on this curve and 
are shown in blue. Quantity is illustrated as plasmid copy number input. The interpolated copy 
number for this clone was around 5300. See more informations and calculations in the text. 
4.2    Second Approach: Comparative Quantification using One Copy Calibrator Samples 
The alternative to identify a potential calibrator clone is to screen for the lowest transgene or marker gene 
expression. We have analyzed GFP expressing HEK-293 clones by FACS, and measured different green 
fluorescent intensities (Figure 7). The fluorescence intensities of the selected clones were compared to 
that of a one copy clone previously identified by absolute quantification. The GFP intensity of this latter 
one was similar to most of the lowest level expressing clones confirming that these clones are suitable for 
reference samples with one copy integration for subsequent analysis. Although expression level can be 
affected by its insertion site, we may say that one copy clones have significantly and uniformly lower 
GFP intensity than the few copy ones, but other transgene expressions may show wider differences. 
Comparative qPCR quantification, while still technically challenging, does not require the same lev-
el of stringency. In this approach, the assay for target sequence is compared to a reference sample (a 
calibrator), and instead of precise copy number determination, it focuses on relative fold changes. In our 
application the copy number can be calculated based on the relative quantity of a single copy insertion. 
The method is based on the assumption that the threshold number of the sample and reference molecules  
 
 
 
 
Figure 7: FACS histograms of representative HEK-293 clones expressing GFP as a transgene. 
Differences in GFP intensities correlate with GFP copy numbers. 
is equal (Livak, 1997): 
RCt Sample = RCt Reference 
where RCt stands for the number of molecules at the threshold cycle. With the theoretical 100% efficien-
cy, PCR duplicates the target in each cycle: 
RCt Sample = R0 Sample × 2Ct Sample 
RCt Reference = R0 Reference × 2Ct Reference 
where R0 Sample and R0 Reference are the initial number of molecules of the sample and reference, 
respectively. The fold difference can therefore be calculated as: 
R0 Sample / R0 Reference = 2–∆Ct, 
where: 
∆Ct = CtSample – CtReference 
However, when the efficiency is not 100% but it is reproducibly identical, efficiency correction should be 
incorporated into the ∆Ct method. 
Fold difference: (1 + E)–∆Ct. 
For each novel assay, it is advisable to determine the efficiency values using the standard curve method-
ology discussed previously. As formerly mentioned, the most suitable specimen for such standard curve 
analysis is pooled gDNA of transgenic clones, because it has similar complexity to the unknown samples 
being analyzed. For comparison, the interpolated values from the standard curves can be used. A concrete 
example for the copy number calculation is as follows: the derived amount of the unknown sample is 
24,99±0,15ng, whereas that of the single copy reference sample is 6.37 ± 0.18ng, so: 
Fold difference – unknown/reference: (24.99 ± 0.15ng)/(6.37 ± 0.18ng) 
Relative quantity (RQ) = 3.93 RQ Min = 3.80 RQ Max = 4.06 
The upper example is still based on comparison of the absolute values of target Ct, however, a sin-
gle Ct does not always reflect the expected number because of specimen discrepancies. Abandoning ab-
solute quantification did not eliminate the deviations arising from differences in sample quality of the 
compared clones. Although the input of the template is always standardized, Ct deviations can still be 
attributable to certain errors, such as DNA concentration measurements. Normalization to an endogenous 
control sequence can overcome this problem. The control sequence should be similar in abundance to the 
target sequence and it must be present at a consistent level among all samples being compared. As an 
endogenous control for the human genome, the RPPH1 gene (the H1 RNA subunit of the RNaseP en-
zyme complex) was chosen which is a widely-accepted one copy gene of the haploid human genome. As 
mentioned earlier, without knowing the efficiency values, standard curves of both sequences have to be 
applied (Figure 8). 
 
 
Figure 8: Example of a relative standard curve experiment. Standard curves for GFP 
and RNaseP (RPPH1) TaqMan® assay can be seen. Dilutions were made from pooled 
gDNA of unknown clones analyzed in the measurement; quantity is expressed in 
nanograms of gDNA input. Regression lines calculated from the measurement points of 
the two assays are parallel to each other, indicating very similar efficiency values. Red 
points represent points of the standard curves, whereas blue ones represent 
measurements of examined clones. See more informations and calculations in the text. 
A relative standard curve experiment is based on sequential comparisons. First, both the target and 
the endogenous control are interpolated separately from the respective standard curves. Specimen com-
parisons showed formerly can be carried out only after normalizations to the endogenous control, for 
example: 
Normalizations – Target/EndCont: 
Sample → (54.23 ± 2.60ng) / (42.34 ± 0.82ng) 
Reference → (6.13 ± 0.70ng)/(19.43 ± 0.25ng) 
Fold difference – Sample/Reference: 
Relative quantity (RQ) = 4.07 RQ Min = 3.76    RQ Max = 4.35 
Alternatively, comparative analysis could be based on the real efficiency values: 
Fold difference – Difference in the target/Difference in the endogenous control: 
(1 + ETarget) –∆Ct Target / (1 + EEndCont) –∆Ct EndCont 
where: 
∆CtTarget = CtTarget Sample – CtTarget Reference 
∆CtEndCont = CtEndCont Sample – CtEndCont Reference  
 
However, if efficiencies of both the target and the endogenous control are proven to be close to identical, 
the ∆∆Ct method could be chosen: 
Fold difference: (1 + E) –∆∆Ct 
where: 
∆∆Ct = ∆CtTarget – ∆CtEndCont 
Ideally, efficiencies of both the target and the endogenous control are close to 100%. 
Fold difference: 2–∆∆Ct 
The main requirement for the ∆∆Ct method is that the efficiencies of the assays are identical. The devia-
tion of the two efficiencies can be determined by plotting the ∆Ct-s from the standard curves points, and 
if the slope of this so called relative efficiency plot (Figure 9) is in the range of < 0.1, then it is acceptable 
to employ the ∆∆Ct method. Another way to test the applicability is analyzing the relative standard curve 
experiment data with the ∆∆Ct method. Similar outcome of the two methods will show the acceptability 
of the comparative Ct method, and in such cases, standard curves can be leaved behind. As the GFP se-
quence worked well in combination with the RPPH1 endogenous control, we continued to examine if 
assays designed for SB transposon sequences can also be utilized for copy number determination with 
similar methodology. 
 
 
Figure 9: Relative efficiency plot comparing TaqMan® assays of IRDR-L and RNaseP 
(RPPH1). Dilution series were prepared from pools of gDNA containing one copy of SB 
transposon. Absolute values of ∆Ct (target minus endogenous control) from the standard curve 
points were plotted against gDNA quantities and the equation of the regression line calculated 
from the measurement points is shown. A line with a slope of very small value (close to 0) 
indicates identical efficiencies of the two assays across all input concentrations. 
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4.3  Third Approach: Comparative Quantification using the SB IRDR Sequence Independently of 
the Transgene 
As the SB transposon system is generally applied in our laboratory, we aimed at developing a real-time 
PCR-based technique that is transgene-independent, specific for the transposon regions, and therefore 
widely applicable. As for most transposon flanking sequences, the two IRDR regions are repeat-rich 
DNA sequences which make PCR primer design relatively difficult. Moreover, the left and the right IR-
DRs are very similar to each other which further narrows the possibility to design specific assays for 
them. Nevertheless, we could still develop specific TaqMan® assays for each: neither of the IRDR-L nor 
the IRDR-R probe set gives signals in the exclusive presence of the other template. 
Next we tested both assays designed for the transposon sequences, whether these fit to the GFP 
copy numbers. As formerly mentioned, random integrations can be the result from the breakage of the 
plasmid at any points, therefore randomly integrated one copy clones are not reliable candidates for ref-
erence samples when utilizing transposon sequences. Only after validating the one copy candidates 
cloned from the active transposition experiments with the GFP assay, were these clones used as reference 
samples with the transposon specific assays. The results based on GFP and the IRDR-L were in agree-
ment with each other (Figure 10) and most standard curve analysis showed similar result with the com-
parative Ct method indicating that we could directly use the ∆∆Ct method. In addition, technical errors 
could be further decreased using a pool of gDNA samples with known copy number as a reference. Here 
we show the calculation with the row Ct values by the example of G2C2 clone in Figure 10 with Cts 
resulted in IRDR-L assay. Ct mean values are calculated as the mean of Cts of 3 simultaneous PCR reac-
tions: 
Ct Mean IRDR-L of G2C2: 31.065 
Ct Mean RNaseP of G2C2: 30.951 
Ct Mean IRDR-L of one copy clone pool: 31.457 
Ct Mean RNaseP of one copy clone pool: 29.773 
Calculations of ∆Ct – s: 
∆Ct IRDR-L = 31.065-31.457 = –0.392 
∆Ct RNaseP = 30.951-29.773 = 1.178 
Calculation of ∆∆Ct: ∆∆Ct = –0.392 – 1.178 = –1.57 
Relative quantity: RQ = 2-∆∆Ct  = 21.57  = 2.969 (3 copies) 
 
These experiments therefore supported the use of the IRDR-L repeat specific assay for transposon 
copy number determination as it gave the same results as the assay specific for the carried internal 
transgene (GFP). However similar application of IRDR-R TaqMan® assay for the previously analyzed 
clones was unreliable to determine the exact copy number and the assay usually showed lower efficiency 
than the GFP and the IRDR-L. So initially we concluded that we have to leave out the specific but less 
efficient assay for the IRDR-R region (Kolacsek et al., 2011). 
 Figure 10: Copy numbers determined by the GFP or the IRDR-L TaqMan® assays in different 
clones of HEK-293 (left panel) and human embryonic stem cells (right panel). Results of the 
transgene independent, SB transposon specific IRDR-L assay correlated well with the GFP-
based copy numbers. Pool: a mixture of equal amounts of one copy clones. Figure partially 
adopted from Kolacsek et al., Mobile DNA (2011), 2(1):5, published by BioMed Central. 
Concerning SB transposon mutants and variants, “symmetrical” SB transposons with two IRDR-L 
(but not with two IRDR-R) flanking sequences were shown to be functional (Izsvak et al., 2002). The 
assay for the left transposon sequence is also applicable for such constructs with a correction factor of 0.5. 
Searching for such mutant transposon clones, we used the IRDR-R assay to determine the presence of the 
right terminal repeat sequence. During this presence-absence examination studies, we could achieve 
higher sensitivity of the IRDR-R TaqMan® with elevating the input range of the gDNA. However, the 
sensitivity and the reliability of IRDR-R was still below to that of the IRDR-L assay, and only lower 
copy number clones showed reliable measurements (Figure 11). In addition, we still have to emphasize 
here that sample quality has a deep impact on reproducibility of all assays. 
As a major general recommendation, we routinely analyze more parts of the inserted transgene se-
quence (e.g. IRDR-L and GFP regions or IRDR-L and IRDR-R regions). It is also advisable using at least 
two separate single copy clones as reference samples and two few copy (3 – 4) clones as controls in all 
analyses. The application of more than one reference clone makes it possible to choose the most appro-
priate one with which low copy control clones give the best precise round copy numbers. In fact, the use 
of the few (3 – 4) copy clones as references is helpful to approximate extreme copies (> 15) more pre-
cisely. 
5  Validation of Transgene-independent qPCR Copy Number Quantifi-
cation 
To compare our transgene-independent quantification approach with other techniques, we measured copy 
numbers of clones that were generated from different cell types by transposons containing various 
transgene sequences. Such clones were ideal for comparison due to the different transgene sequence and 
because copy numbers in those cases were also determined either by the Southern/dot blotting techniques,  
 
 
 
Figure 11: Comparison of transposon copy number determinations based on three 
different TaqMan® assays. Using higher amount of input gDNA (90ng) resulted in 
reliable correlation of the IRDR-R assay with the copy numbers determined by the 
GFP and IRDR-L specific qPCR measurements. 
or by the transposon display method, or by estimations from transgene integration assays (Splinkerette 
PCR/Inverse PCR). Using the IRDR-L assay with the ΔΔCt methodology, copy numbers were estimated 
ranging from 1 to 50 copies in various clones (Table 1 and 2). The measured transposon copies were 
almost always the same by the qPCR as by the canonical methods. As canonical methods – with the ex-
ception of dot blot – utilize restriction enzyme sites flanking the integration point, which may be sensi-
tive to sequence environment, therefore all integrated copies may not be reliably detected by the canoni-
cal methods. Perhaps this is why copy numbers were underestimated in some of the cases comparing to 
our qPCR method. For higher (> 5) copy-number clones, our method was also accurate, with occasional 
low relative-error margins (≤ 9%). The slight differences in these cases could be due to the inaccuracy of 
the standard methods for this range. In addition, it has been suggested that precise values of very high 
copy numbers are more reliably measured by dot blot rather than transposon display method. 
By the above described experiments, the newly developed transgene independent method for de-
termining SB transposon copy numbers could be validated since (i) it provided the same results as the 
assays specific for the carried transgene sequence and (ii) it could also reliably replace widely used ca-
nonical radioactive techniques. The TaqMan® assay designed for the IRDR-L region of the transposon 
provides the basis for transgene independence as it is present in all SB constructs (Kolacsek et al., 2011). 
 
 
 
 
 
 
 
 
Table 1: Comparing the IRDR-L qPCR-based method with other canonical techniques for 
transposon copy number determination. Additional data is added to the table adopted from 
Kolacsek et al., Mobile DNA (2011), 2(1):5, published by BioMed Central. 
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6    Quantitative Excision PCR 
In our laboratory, we have successfully applied different DNA transposon systems for various in vitro 
cell culture applications, including studies on directed tissue differentiation from embryonic stem cells 
and modeling ex vivo introduction of therapeutic transgenes into patient cells. Controlling the delivery 
efficiency is a crucial task for these applications which is usually characterized by testing the transgenic 
rate of transfectants. However these test methods are time consuming and not applicable in all of the 
cases, so we have developed a qPCR method to characterize transposition activity. This quantification is 
extremely useful when optimizing for conditions of a given delivery system, or comparing the efficiency 
of different transposon systems or variants of a particular transposase enzyme.  
There are two major steps involved in transposition, the excision of the transposon from the donor 
site and the integration of the transposon into the target site. These steps are proven to be coupled since 
excision frequency of different transposon mutants from a donor plasmid was correlated to overall trans-
position efficiency (Liu et al., 2004). Excision events can be detected by a PCR reaction with primers 
flanking the transposon sequence at the donor site (Figure 12). Following excision, the donor plasmid 
will be circularized by the double-strand DNA break repair mechanism of the cell, and only these excised 
and repaired plasmids will serve as a template for exponential amplification, because the transposon con-
tent is usually large enough not to be amplified from the original uncut sequence. Excision PCR can be 
carried out on samples taken on the second/third day after transfection, and both isolated plasmids, as 
well as cell lysates can be used as input material (we generally use isolated plasmids as input.) A semi 
quantitative version of this excision PCR has been applied by Liu et al. (2004) to describe the excision 
step of SB transposition. 
 
 
Figure 12: Principle of the excision PCR using transposon containing donor plasmids. This is 
a nested PCR technique using two sets of primers specific to the transposon flanking 
sequences, and amplifying the products in two consecutive rounds of PCR. In case of 
transposition (SB+), there is a distinct product that can be visualized by agarose gel 
electrophoresis (right panel). In the absence of transposition (SB-), the PCR cannot amplify 
the target sequence due to its large size. For more details, see the text.  
Due to the error-prone double-stranded break repair mechanism, the joining of the donor ends is 
remarkably imprecise, therefore real-time quantification of excision based on a TaqMan® probe with 
stringent sequence requirement could not be considered, and hence we adopted the SYBR® Green tech-
nology for this application. In some cases, since very small portion of the amount of transposon donor 
plasmids undergo excision, to increase the traceability, more than one round of nested PCR is necessary 
to quantify the excision reaction. For this reason, we apply a 10 – 13 cycle pre-amplification (first round 
of PCR), and after a thousand-fold dilution we measure the real-time round (second round of PCR) with 
nested primers using SYBR® Green. Amplification from another segment of the plasmid backbone (in 
our case, the ampicillin resistance gene sequence) could serve as a normalization control. Due to its large 
excess, ampicillin sequence is not pre-amplified but it is permanently present in our samples during all 
processes until the second round of excision PCR, so it can be correctly measured in all samples. Alt-
hough the primers we routinely use are specific to the backbone of our transposon plasmid constructs 
which can differ among SB users, our primers might be useful for those who apply constructs with the 
same origin (Table 3). PCR efficiencies for the target and the control sequence were measured by serial 
dilutions of pooled samples and the ∆∆Ct method was proved to be reliable for comparison of excision 
efficiencies. 
 
 
Table 3: Sequences of primers used for the quantitative excision PCR. Primers with .1 
extension are used for the first round, whereas others with .2 extension are used for the second 
round of the nested PCR; amp primers anneal to the sequence of the ampicillin resistance gene. 
An excellent validation of our quantification method developed for measuring the transposition ac-
tivity was to compare different SB transposase versions resulted from gradual improvement of the activi-
ty (Mates et al., 2009). Relative quantification of excision efficiency of SB11x, SB32x and SB100x is 
correlated to their expected activity in HEK-293 and in HeLa cells as well (Figure 13). 
Normalization to the plasmid backbone sequence makes this relative quantification technique in-
dependent of the transfection efficiency. This provides the basis for comparing various transposon deliv-
ery experiments, including different transposon systems (e.g. SB or PB), different transposase or trans-
poson variants, different host cell types, or different experimental settings. Applying this quantitative 
technique could therefore be a reliable and fast screening approach for different transposon systems and 
gene delivery conditions before any applications with the desired transgene. 
 
Figure 13: Relative excision efficiencies of SB transposase variants in different cell lines measured 
by real-time qPCR. Normalizing the excision PCR to the amount of the ampicillin sequence by 
specific PCR, here we quantify the excision events among all transfected transposon donor plasmids. 
7    Related Works 
As it was used for quantitative aspects of transposon-based gene delivery experiments, real-time PCR 
measurements are widely used and have become integral part of the methodology for gene delivery and 
gene therapy applications. On the other hand, careful design of the experiments or choosing suitable 
methodology are often missing from such studies, weakening the conclusion of the results. For example, 
Bian & Belmont (2010) have made absolute quantification of transgenic multi-copy insertions derived 
from linearized plasmid transfection, although they did not carry out any normalization of the input mate-
rial. Huang et al. (2010) have detected random integration level with absolute quantification normalizing 
to the RNaseP one copy sequence. They used “empty” gDNA to mix with the target sequence containing 
plasmid for the standard curve samples; however, normalizing the absolute quantification with external 
template incorporates additional variability in the measurement. In the meantime, well-designed studies 
provide excellent new examples of combining existing technologies. Charrier et al. (2011) have applied 
an elegant solution for absolute quantification to determine lentiviral vector copy numbers with normali-
zation to endogenous albumin. Standard curves were made from the same plasmid containing both the 
target and the endogenous control sequence, resulting in the smallest possible variability in their meas-
urement. Ballester et al. (2004) determined copy number of transgenic mice carrying goat lactoglobulin 
gene using relative quantification with the comparative Ct method. The unique design of the measure-
ment was the application of goat gDNA as a reference sample and the choice of glucagon sequence as an 
endogenous control, the latter one being strongly conserved between the two species. 
Concerning SB transposon applications, a recent paper described a simultaneous analysis of exci-
sion activity of Sleeping Beauty and the resulting transgene copy number (Jin et al., 2011). Excision was 
analyzed at days 1 to 3 after electroporation using the ∆∆Ct method with a TaqMan® assay where the 
probe was specific to one of the transposon flanking regions. They also normalized to a plasmid back-
bone sequence, thus similarly to our qPCR studies, their quantification is independent of the electrotrans-
fer efficiency. However, as the repair of the plasmid after excision is an error-prone process (see Section 
7), using a strict TaqMan® probe sequence may not detect all excision products. They also determined the 
average copy number in transgenic cell population after four weeks of selection. They used an absolute 
quantification approach using dilution series of a one copy clone gDNA as a standard which is in fact an 
alternative to relative standard curve method using one copy as a reference. 
8    Conclusions 
Transposon-based technology is an emerging new method of choice for gene delivery and for gene thera-
py applications. Compared to viral vectors, transposon systems offer several advantages. Apart from 
being less expensive in terms of the required safety facilities, for several DNA transposons, the integra-
tion profile of the delivered transgene is more close to random, showing no preferences for coding re-
gions, therefore making its application less susceptible for insertional mutagenesis. SB seems to be the 
safest delivery technique for two reasons: 1) its transgene integration profile is the closest to random 
among all known gene delivery vehicles; 2) SB was resurrected from an ancient non-functional fish mo-
bile element, therefore no potential transposons are present in vertebrate species, including the human 
genome, that can remobilize the integrated transgene. Based on these characteristics, the SB system is the 
most suitable for cell and gene therapy applications, even if compared to other transposon vehicles. 
Our work contributed to the quantification of transposon delivery in two important aspects. We 
have developed sensitive and reliable real-time PCR-based methods to measure (i) the first step of the 
transposition and (ii) the resulting copy number of the delivery. Quantitative excision PCR is extremely 
useful to control and to optimize transposon mediated gene delivery, whereas copy number determination 
is essential to characterize transgenic cells. Comparing our copy number method with widely used canon-
ical methods, it was proved to be just as accurate as those, also offering a faster and non-radioactive ap-
proach at the same time. However, the real advantage of this method is the transgene-independence 
which makes it applicable for any scientists working with SB transposon constructs. 
In this chapter, we gave a detailed protocol for designing quantitative measurements of integrated 
DNA sequences such as transposons, and show examples for developing reliable quantitative assays 
specific to any sequence. In general, however, this description may also serve as a stepwise guide provid-
ing a strategy for similar quantification purposes. 
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